Literature DB >> 19822893

Immune restoration diseases reflect diverse immunopathological mechanisms.

Patricia Price1, David M Murdoch, Upasna Agarwal, Sharon R Lewin, Julian H Elliott, Martyn A French.   

Abstract

Up to one in four patients infected with human immunodeficiency virus type 1 and given antiretroviral therapy (ART) experiences inflammatory or cellular proliferative disease associated with a preexisting opportunistic infection, which may be subclinical. These immune restoration diseases (IRD) appear to result from the restoration of immunocompetence. IRD associated with intracellular pathogens are characterized by cellular immune responses and/or granulomatous inflammation. Mycobacterial and cryptococcal IRD are attributed to a pathological overproduction of Th1 cytokines. Clinicopathological characteristics of IRD associated with viral infections suggest different pathogenic mechanisms. For example, IRD associated with varicella-zoster virus or JC polyomavirus infection correlate with a CD8 T-cell response in the central nervous system. Exacerbations or de novo presentations of hepatitis associated with hepatitis C virus (HCV) infection following ART may also reflect restoration of pathogen-specific immune responses as titers of HCV-reactive antibodies rise in parallel with liver enzymes and plasma markers of T-cell activation. Correlations between immunological parameters assessed in longitudinal sample sets and clinical presentations are required to illuminate the diverse immunological scenarios described collectively as IRD. Here we present salient clinical features and review progress toward understanding their pathogeneses.

Entities:  

Mesh:

Year:  2009        PMID: 19822893      PMCID: PMC2772363          DOI: 10.1128/CMR.00015-09

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  155 in total

1.  Hepatitis C viraemia in HIV-HCV co-infected patients having immune restoration with highly active antiretroviral therapy.

Authors:  M Pérez-Olmeda; J García-Samaniego; V Soriano
Journal:  AIDS       Date:  2000-01-28       Impact factor: 4.177

Review 2.  Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy.

Authors:  W J Burman; B E Jones
Journal:  Am J Respir Crit Care Med       Date:  2001-07-01       Impact factor: 21.405

3.  Herpes zoster infection in HIV-seropositive patients associated with highly active antiretroviral therapy.

Authors:  T Aldeen; P Hay; F Davidson; R Lau
Journal:  AIDS       Date:  1998-09-10       Impact factor: 4.177

4.  Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients.

Authors:  Shelley F Stone; Silvia Lee; Niamh M Keane; Patricia Price; Martyn A French
Journal:  J Infect Dis       Date:  2002-10-23       Impact factor: 5.226

5.  Varicella zoster as a manifestation of immune restoration disease in HIV-infected children.

Authors:  Nutthapong Tangsinmankong; Wasu Kamchaisatian; Jorge Lujan-Zilbermann; Cynthia L Brown; John W Sleasman; Patricia J Emmanuel
Journal:  J Allergy Clin Immunol       Date:  2004-04       Impact factor: 10.793

6.  Immune reconstitution inflammatory syndrome among HIV/AIDS patients during highly active antiretroviral therapy in Addis Ababa, Ethiopia.

Authors:  Kahsay Huruy; Andargachew Mulu; Getahun Mengistu; Aster Shewa-Amare; Addis Akalu; Afework Kassu; Gashaw Andargie; Daniel Elias; Workineh Torben
Journal:  Jpn J Infect Dis       Date:  2008-05       Impact factor: 1.362

7.  Immune reconstitution inflammatory syndrome presenting as pericarditis and pericardial effusion.

Authors:  Alwyn Rapose; Bilal Sarvat; Juan C Sarria
Journal:  Cardiology       Date:  2007-10-31       Impact factor: 1.869

8.  Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide.

Authors:  T R Kozel; J Cazin
Journal:  Infect Immun       Date:  1971-02       Impact factor: 3.441

9.  Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage.

Authors:  Claire Dunn; Maurizia Brunetto; Gary Reynolds; Theodoros Christophides; Patrick T Kennedy; Pietro Lampertico; Abhishek Das; A Ross Lopes; Persephone Borrow; Kevin Williams; Elizabeth Humphreys; Simon Afford; David H Adams; Antonio Bertoletti; Mala K Maini
Journal:  J Exp Med       Date:  2007-03-12       Impact factor: 14.307

10.  Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells.

Authors:  D D Taub; A R Lloyd; K Conlon; J M Wang; J R Ortaldo; A Harada; K Matsushima; D J Kelvin; J J Oppenheim
Journal:  J Exp Med       Date:  1993-06-01       Impact factor: 14.307

View more
  21 in total

1.  Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand.

Authors:  Anchalee Avihingsanon; Gail V Matthews; Sharon R Lewin; Pip Marks; Jose Sasadeusz; David A Cooper; Scott Bowden; Stephen Locarnini; Greg J Dore; Kiat Ruxrungtham
Journal:  AIDS Res Ther       Date:  2012-03-09       Impact factor: 2.250

2.  [Immune reconstitution syndrome].

Authors:  D Meyer-Olson; D Ernst; M Stoll
Journal:  Z Rheumatol       Date:  2012-04       Impact factor: 1.372

3.  Selective expansion of polyfunctional pathogen-specific CD4(+) T cells in HIV-1-infected patients with immune reconstitution inflammatory syndrome.

Authors:  Yolanda D Mahnke; Jamieson H Greenwald; Rebecca DerSimonian; Gregg Roby; Lis R V Antonelli; Alan Sher; Mario Roederer; Irini Sereti
Journal:  Blood       Date:  2012-01-04       Impact factor: 22.113

4.  Natural killer cell activation distinguishes Mycobacterium tuberculosis-mediated immune reconstitution syndrome from chronic HIV and HIV/MTB coinfection.

Authors:  Francesca Conradie; Andrea S Foulkes; Prudence Ive; Xiangfan Yin; Katerina Roussos; Deborah K Glencross; Denise Lawrie; Wendy Stevens; Luis J Montaner; Ian Sanne; Livio Azzoni
Journal:  J Acquir Immune Defic Syndr       Date:  2011-11-01       Impact factor: 3.731

Review 5.  Biomarkers in immune reconstitution inflammatory syndrome: signals from pathogenesis.

Authors:  Irini Sereti; Alison J Rodger; Martyn A French
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

Review 6.  Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy.

Authors:  Stephen D Lawn; Graeme Meintjes
Journal:  Expert Rev Anti Infect Ther       Date:  2011-04       Impact factor: 5.091

Review 7.  Immune reconstitution reactions in human immunodeficiency virus-negative patients: report of a case and review of the literature.

Authors:  Tiffany C Scharschmidt; Erin H Amerson; Oren S Rosenberg; Richard A Jacobs; Timothy H McCalmont; Kanade Shinkai
Journal:  JAMA Dermatol       Date:  2013-01       Impact factor: 10.282

8.  Multi-analyte profiling of ten cytokines in South African HIV-infected patients with Immune Reconstitution Inflammatory Syndrome (IRIS).

Authors:  Catherine M Worsley; Melinda S Suchard; Wendy S Stevens; Annelies Van Rie; David M Murdoch
Journal:  AIDS Res Ther       Date:  2010-10-07       Impact factor: 2.250

Review 9.  HIV and co-infections.

Authors:  Christina C Chang; Megan Crane; Jingling Zhou; Michael Mina; Jeffrey J Post; Barbara A Cameron; Andrew R Lloyd; Anthony Jaworowski; Martyn A French; Sharon R Lewin
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

Review 10.  Tuberculosis Immune Reconstitution Inflammatory Syndrome in children initiating Antiretroviral Therapy for HIV infection: A systematic literature review.

Authors:  Ruth Link-Gelles; Harry Moultrie; Shobna Sawry; David Murdoch; Annelies Van Rie
Journal:  Pediatr Infect Dis J       Date:  2014-05       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.